ERBB2 and breast cancer: Luminal and HER2-enriched subtypes are associated with good prognoses and are highly responsive to therapy, resulting in a greatly improved outcome, while TNBC is the most aggressive subtype of BC, which is characterized by a high cell proliferation rate and a tendency to relapse [8].